Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Oxytocin Gel for Vaginal Atrophy in Postmenopausal Women
NCT05627791Phase 3Terminated
- Sponsor
- Ministry of Public Health
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxytocin nasal spray in Vulvovaginal atrophy (VVA) (2 arms), sponsored by Ministry of Public Health. Primary endpoint: Vaginal Maturation Index at 8 weeks. Started Nov 2022; status: terminated.
02
Drugs
oxytocin nasal spray
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT05627791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627791.